Immunology
Myositis
13
Pipeline Programs↗
3
Active Trials↗
11
Companies Involved↗
Myositis is an emerging landscape with 13 programs across 11 companies. The most active players are Cartesian Therapeutics, Glaxo Dba Glaxosmithkline, Hope Pharmaceuticals. 3 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 27
Analysis
Modality Breakdown
13programs
Small molecule754%
Monoclonal antibody323%
Cell therapy215%
Protein / enzyme18%
Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
8
clinical trials
Completed4 · 50%
Not yet recruiting2 · 25%
Unknown status1 · 13%
Active, not recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
Add-on Intravenous Immunoglobulins in Early Myositis
Active, not recruiting·—·Phase 2/3·NCT05832034·44 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)